Compare CVS Health Corp (CVS) vs VanEck Semiconductor ETF (SMH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs VanEck Semiconductor ETF — how do they compare? CVS Health Corp trades at $86.25 (market cap $112.49B), while VanEck Semiconductor ETF trades at $617.07 (market cap $76.96B). The key difference: CVS Health Corp is the larger of the two by market cap, and CVS Health Corp pays a 3.02% dividend while VanEck Semiconductor ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and VanEck Semiconductor ETF for 101 Days on average.
| CVS | SMH | |
|---|---|---|
Market Cap | $112.49B | $76.96B |
Volume | 8,467,392 | 7,093,686 |
Sector | Health | — |
52-Week High | $110.60 | $668.91 |
52-Week Low | $70.08 | $325.10 |
Typical Hold Time | 83 Days | 101 Days |
Enterprise Value | $174.83B | — |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
SMH (VanEck Semiconductor ETF) trades at $625.03, down 1.18% on the day but maintains strong bullish momentum with 69% year-to-date gains as of September 30, 2026. The ETF benefits from semiconductor sector strength, with technical indicators showing bullish moving averages but overbought RSI levels. Recent news highlights the fund's outperformance versus individual chip stocks and ongoing AI-driven demand.
Outlook remains positive given semiconductor market expansion projections, though concentration risk in top holdings and sector volatility present challenges. Bank of America forecasts the global chip market to nearly double by 2030, supporting long-term growth potential despite near-term technical overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →
